Search company, investor...

Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
mt-pharma.co.jp

Investments

1

Partners & Customers

10

About Mitsubishi Tanabe Pharma

Mitsubishi Tanabe Pharma (TYO: 4508) is a research-driven pharmaceutical company based in Japan, specializing in research, development, and marketing of globally competitive pharmaceutical products focused on the field of autoimmune disease, diabetes and kidney disease, and CNS disease.

Headquarters Location

3-2-10, Dosho-machi Chuo-ku

Osaka, 541-8505,

Japan

+81-6-6205-5085

Want to inform investors similar to Mitsubishi Tanabe Pharma about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Mitsubishi Tanabe Pharma News

Atopic disease severity impacts quality of life in Japanese pediatric patients

Sep 1, 2023

Disclosures: Ohya reports having financial relationships with AbbVie, Eli Lilly Japan K.K., Fam Pharma, Kao, and Maruho Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co. Ltd., Pfizer, Pola Pharma Inc., Sanofi K.K., Sinopharm, Taiho Pharmaceutical Co. Ltd., Thermo Fisher Scientific, and Torii Pharmaceutical Co. Ltd. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Key takeaways: Children and adolescents with more severe atopic dermatitis had worse quality of life than those with mild disease. Hospitalizations, school absences and comorbidities all increased with disease severity. Greater atopic dermatitis severity correlated with greater disease burden in children and adolescents in Japan, according to a study. “Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin condition characterized by symmetrically distributed pruritic dermatitis that usually appears during infancy/childhood,” Yukihiro Ohya, MD, PhD, of the allergy center at the National Center for Child Health and Development in Tokyo, and colleagues wrote. “AD in childhood/adolescence is associated with atopic comorbidities and significant patient burden, including reduced health-related quality of life (HRQoL).” Greater atopic dermatitis severity correlated with greater disease burden in children and adolescents in Japan. Image: Adobe Stock. Pediatric populations across several countries were included in the real-world Epidemiology of Children with Atopic Dermatitis reporting on their Experience (EPI-CARE) study; however, this analysis focused on those in the study from Japan. Patients aged 6 months to 17 years were included in the survey, which consisted of a 30-minute questionnaire to be completed by caregivers or patients. The survey included demographic data, severity evaluations and AD impact on disease burden. Of 5,702 Japanese patients in the EPI-CARE database, 10.7% were diagnosed with AD, with 63.3% having clear or mild disease, 32.5% having moderate disease and 4.4% having severe disease. In all age groups, those with higher disease severity had increased symptom severity, number of flares and comorbidities , the most common being hay fever, allergic rhinitis, asthma and seasonal allergies. Greater disease severity was also linked to increased health care utilization and more absences from school, in addition to worse HRQoL. ED visits requiring hospitalization in the 12 months preceding the study were 2.9% in those with mild disease, 9.2% in those with moderate disease and 20.5% in those with severe disease. School absences were approximately three times higher in those with moderate or severe disease compared with those with mild disease. Quality of life, as measured by the HRQoL, was worse for all patients with more severe disease , but in children aged 6 to 12 years it was particularly worse, according to the study. “This population-based study of Japanese pediatric patients aged 6 months to [younger than] 18 years describes the comprehensive AD burden of patients with moderate/severe forms of the disease and highlights the medical need for safe treatments offering long-term disease control,” the authors wrote. Read more about

Mitsubishi Tanabe Pharma Investments

1 Investments

Mitsubishi Tanabe Pharma has made 1 investments. Their latest investment was in EditForce as part of their Milestone Payment on July 7, 2022.

CBI Logo

Mitsubishi Tanabe Pharma Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/5/2022

Milestone Payment

EditForce

$146M

Yes

1

Date

7/5/2022

Round

Milestone Payment

Company

EditForce

Amount

$146M

New?

Yes

Co-Investors

Sources

1

Mitsubishi Tanabe Pharma Acquisitions

2 Acquisitions

Mitsubishi Tanabe Pharma acquired 2 companies. Their latest acquisition was NeuroDerm on October 18, 2017.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/18/2017

Other

$99M

$20.5M

Acq - P2P

11

9/18/2013

Other Venture Capital

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

10/18/2017

9/18/2013

Investment Stage

Other

Other Venture Capital

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$20.5M

$99M

Note

Acq - P2P

Subscribe to see more

Sources

11

10

Mitsubishi Tanabe Pharma Partners & Customers

10 Partners and customers

Mitsubishi Tanabe Pharma has 10 strategic partners and customers. Mitsubishi Tanabe Pharma recently partnered with HitGen on February 2, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

2/25/2022

Partner

China

HitGen has successfully completed a three-year collaboration with MTPC to discover novel hit compounds for multiple drug targets

In December 2018 , HitGen Inc. and MTPC entered into a drug discovery research collaboration to identify novel small molecule hits for multiple targets of interest .

3

1/18/2022

Licensor

Switzerland

ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan

`` MTPC is delighted to collaborate with ADC Therapeutics SA , a leader in the field of antibody drug conjugates , to develop and commercialize ZYNLONTA in Japan , '' said Hiroaki Ueno , PhD , Chief Executive Officer of Mitsubishi Tanabe Pharma Corporation .

6

10/25/2021

Licensor

United States

08:07 ET New Analyses Suggest Favorable Results for STELARA® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patie...

In Europe , Russia and Turkey , Janssen Biotech , Inc. licenses distribution rights to REMICADE to Schering-Plough Company , a subsidiary of Merck & Co , Inc. .

1

11/5/2020

Licensor

United States

Subscribe to see more

Subscribe to see more

10

8/18/2020

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

2/25/2022

1/18/2022

10/25/2021

11/5/2020

8/18/2020

Type

Partner

Licensor

Licensor

Licensor

Partner

Business Partner

Country

China

Switzerland

United States

United States

United States

News Snippet

HitGen has successfully completed a three-year collaboration with MTPC to discover novel hit compounds for multiple drug targets

In December 2018 , HitGen Inc. and MTPC entered into a drug discovery research collaboration to identify novel small molecule hits for multiple targets of interest .

ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan

`` MTPC is delighted to collaborate with ADC Therapeutics SA , a leader in the field of antibody drug conjugates , to develop and commercialize ZYNLONTA in Japan , '' said Hiroaki Ueno , PhD , Chief Executive Officer of Mitsubishi Tanabe Pharma Corporation .

08:07 ET New Analyses Suggest Favorable Results for STELARA® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patie...

In Europe , Russia and Turkey , Janssen Biotech , Inc. licenses distribution rights to REMICADE to Schering-Plough Company , a subsidiary of Merck & Co , Inc. .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

6

1

10

10

Mitsubishi Tanabe Pharma Team

2 Team Members

Mitsubishi Tanabe Pharma has 2 team members, including current President, Michihiro Tsuchiya.

Name

Work History

Title

Status

Michihiro Tsuchiya

President

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Michihiro Tsuchiya

Subscribe to see more

Work History

Title

President

Subscribe to see more

Status

Current

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.